Allena has completed two clinical trials with ALLN-177 and has built a broad phase 2 program in preparation for pivotal development. Click the links below for information about our phase 1 and 2 trials and preclinical studies. We will continue to post new publications as they become available.
A Double-Blind, Placebo Controlled, Randomized Phase 1 Cross-Over Study with ALLN-177, an Orally Administered Oxalate Degrading Enzyme
ALLN-177 Reduces Hyperoxaluria in a Porcine Model of Secondary Hyperoxaluria (2°HO) Induced by a Human-like Oxalate Rich Diet
Hyperoxaluria Is Reduced and Nephrocalcinosis Prevented with an Oxalate-Degrading Enzyme in Mice with Hyperoxaluria